Alzheimer’s disease (AD) accounts for 62% of all dementia and represents a major and increasing problem in many developed countries. It  is estimated that the cost of dementia care to the NHS is currently £17 billion per annum. Furthermore, as the average age of the population increases these costs are likely to rise significantly. There are currently around 700,000 people in the UK with dementia and this number is expected to rise to over a million by 2025 and over 1.7 million by 2051. Consequently there is significant effort being directed at developing effective treatments for AD. Imaging biomarkers have a significant role to play in this effort. Such treatments will undoubtedly be expensive and current clinical assessment for AD is inaccurate. There is a need for methods that allow specific diagnosis. Specific markers of AD may be used to diagnose patients, to help in drug development, to select patients who are most likely to benefit from a particular therapy or to monitor their response. Positron Emission Tomography (PET) is the most sensitive method for imaging function in-vivo. Therefore, in this project, we aim to develop specific PET imaging biomarkers for AD.